ATE304365T1 - Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs - Google Patents
Verwendung von humanen prostatazellinien zur behandlung von prostatakrebsInfo
- Publication number
- ATE304365T1 ATE304365T1 AT99959542T AT99959542T ATE304365T1 AT E304365 T1 ATE304365 T1 AT E304365T1 AT 99959542 T AT99959542 T AT 99959542T AT 99959542 T AT99959542 T AT 99959542T AT E304365 T1 ATE304365 T1 AT E304365T1
- Authority
- AT
- Austria
- Prior art keywords
- cell lines
- cancer
- treat
- prostate cancer
- human
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 210000005267 prostate cell Anatomy 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000007660 Residual Neoplasm Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 208000037819 metastatic cancer Diseases 0.000 abstract 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9827104.2A GB9827104D0 (en) | 1998-12-10 | 1998-12-10 | New cancer treatments |
| PCT/GB1999/004129 WO2000033869A2 (en) | 1998-12-10 | 1999-12-09 | Use of human prostrate cell lines in cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304365T1 true ATE304365T1 (de) | 2005-09-15 |
Family
ID=10843926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99959542T ATE304365T1 (de) | 1998-12-10 | 1999-12-09 | Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6972128B1 (enExample) |
| EP (1) | EP1137422B1 (enExample) |
| JP (2) | JP4949554B2 (enExample) |
| KR (1) | KR20010090874A (enExample) |
| AT (1) | ATE304365T1 (enExample) |
| AU (1) | AU763485B2 (enExample) |
| CA (1) | CA2354045C (enExample) |
| CZ (1) | CZ300499B6 (enExample) |
| DE (1) | DE69927286T2 (enExample) |
| ES (1) | ES2249046T3 (enExample) |
| GB (1) | GB9827104D0 (enExample) |
| HU (1) | HUP0104568A3 (enExample) |
| IL (2) | IL143296A0 (enExample) |
| MX (1) | MXPA01005816A (enExample) |
| NO (1) | NO327044B1 (enExample) |
| NZ (1) | NZ512004A (enExample) |
| PL (1) | PL201016B1 (enExample) |
| WO (1) | WO2000033869A2 (enExample) |
| ZA (1) | ZA200104164B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| GB9827103D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| AU4935700A (en) * | 1999-05-21 | 2000-12-12 | Onyvax Limited | New vaccine formulations-3 |
| CA2404388C (en) * | 2000-04-01 | 2010-06-15 | Onyvax Limited | New prostate cell lines |
| US6667479B2 (en) * | 2001-06-01 | 2003-12-23 | Raytheon Company | Advanced high speed, multi-level uncooled bolometer and method for fabricating same |
| US20050019336A1 (en) | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| WO2005023328A2 (en) * | 2003-08-26 | 2005-03-17 | Becton Dickinson And Company | Methods for intradermal delivery of therapeutics agents |
| CN105664147A (zh) * | 2007-02-07 | 2016-06-15 | 日本电气株式会社 | 用于癌症的治疗剂 |
| US20100255020A1 (en) * | 2007-11-20 | 2010-10-07 | Nec Corporation | Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them |
| AU2009200767A1 (en) * | 2008-03-10 | 2009-09-24 | Aristocrat Technologies Australia Pty Limited | A gaming system and a method of gaming |
| CA2743904A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE230615T1 (de) * | 1991-10-04 | 2003-01-15 | Whitehead Biomedical Inst | Regulierung der systemischen immunantworten mittels zytokinen und antigenen |
| JPH05246889A (ja) * | 1992-03-05 | 1993-09-24 | Seitai Chiyousetsu Kenkyusho:Kk | 制癌方法および制癌剤 |
| WO1995029704A1 (en) * | 1994-04-28 | 1995-11-09 | Scott Freeman | Cell lines obtained by in vivo migration and by fusion with autoimmune cells |
| JP3201610B2 (ja) * | 1995-03-17 | 2001-08-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍を処置する方法 |
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| ES2191784T3 (es) * | 1995-12-28 | 2003-09-16 | Univ Johns Hopkins Med | Vacunas de tumores de citocinas paracrinas alogenicas. |
| EP0877798B1 (en) * | 1996-02-02 | 2003-05-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
| GB9620350D0 (en) * | 1996-09-30 | 1996-11-13 | Maudsley David J | Cancer vaccine |
| US6207805B1 (en) * | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
-
1998
- 1998-12-10 GB GBGB9827104.2A patent/GB9827104D0/en not_active Ceased
-
1999
- 1999-12-09 ES ES99959542T patent/ES2249046T3/es not_active Expired - Lifetime
- 1999-12-09 CZ CZ20012032A patent/CZ300499B6/cs not_active IP Right Cessation
- 1999-12-09 NZ NZ512004A patent/NZ512004A/en unknown
- 1999-12-09 IL IL14329699A patent/IL143296A0/xx active IP Right Grant
- 1999-12-09 AT AT99959542T patent/ATE304365T1/de not_active IP Right Cessation
- 1999-12-09 HU HU0104568A patent/HUP0104568A3/hu unknown
- 1999-12-09 KR KR1020017007096A patent/KR20010090874A/ko not_active Ceased
- 1999-12-09 PL PL348828A patent/PL201016B1/pl not_active IP Right Cessation
- 1999-12-09 US US09/857,691 patent/US6972128B1/en not_active Expired - Lifetime
- 1999-12-09 CA CA2354045A patent/CA2354045C/en not_active Expired - Fee Related
- 1999-12-09 JP JP2000586359A patent/JP4949554B2/ja not_active Expired - Fee Related
- 1999-12-09 WO PCT/GB1999/004129 patent/WO2000033869A2/en not_active Ceased
- 1999-12-09 EP EP99959542A patent/EP1137422B1/en not_active Expired - Lifetime
- 1999-12-09 MX MXPA01005816A patent/MXPA01005816A/es active IP Right Grant
- 1999-12-09 DE DE69927286T patent/DE69927286T2/de not_active Expired - Lifetime
- 1999-12-09 AU AU16683/00A patent/AU763485B2/en not_active Ceased
-
2001
- 2001-05-22 ZA ZA200104164A patent/ZA200104164B/en unknown
- 2001-05-22 IL IL143296A patent/IL143296A/en not_active IP Right Cessation
- 2001-05-29 NO NO20012634A patent/NO327044B1/no not_active IP Right Cessation
-
2005
- 2005-07-12 US US11/178,415 patent/US8034360B2/en not_active Expired - Fee Related
-
2011
- 2011-10-07 JP JP2011223318A patent/JP2012021028A/ja active Pending
- 2011-10-11 US US13/270,820 patent/US20120164099A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20021830L (no) | Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| DE60037394D1 (de) | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE | |
| ATE501722T1 (de) | Therapeutische behandlung androgenrezeptorbedingter leiden | |
| AR023400A1 (es) | Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores | |
| DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
| DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| NZ332720A (en) | Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia | |
| DE69927286D1 (de) | Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs | |
| MXPA01010982A (es) | Uso de phyllanthus para la estimulacion dirigida al objetivo del sistema inmune. | |
| ATE296839T1 (de) | Antikörper zur krebsbehandlung und -diagnose | |
| WO2002066044A3 (en) | Method for dendritic cells based immunotherapy of tumors using combination therapy | |
| WO2023164455A3 (en) | Compositions and methods to modulate the immune system | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| AU6083301A (en) | Treating eczema and/or psoriasis | |
| ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
| IS5570A (is) | Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni | |
| ATE283920T1 (de) | Verfahren zur immunisierung und behandlung von h. pylori infektion | |
| DK1133296T3 (da) | Ny terapeutisk anvendelse af nicergolin | |
| DE60123138D1 (de) | Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs | |
| ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma | |
| ATE302009T1 (de) | Ubichinon qn zur behandlung von migräneschmerzen | |
| ATE419370T1 (de) | Lentivirale vektoren zur behandlung von schmerzen | |
| ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| ATE541566T1 (de) | Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |